Earnings Call for Q1FY22 of Alkem Laboratories
Conference Call with Alkem Laboratories Management and Analysts on Q1FY22 Performance and Outlook. Listen to the full earnings transcript.06-08-2021
06-08-2021
Alkem Laboratories Ltd - 539523 - Closure of Trading Window
We refer to our earlier communication dated 25th June, 2021 regarding closure of trading window (for the purpose of financial results for the quarter ended 30th June, 2021) starting from 29th June, 2021 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter ended 30th June, 2021 are communicated to the Stock Exchanges. The Financial Results of the Company for the quarter ended 30th June, 2021 having been communicated to the Stock Exchanges, today i.e. 06th August, 2021, the trading window shall open on 09th August, 2021.06-08-2021
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Investor Presentation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith press release and analyst presentation on Q1FY22 earnings and business updates and the same will be uploaded on the website of the Company. Kindly take note of the same.06-08-2021
Alkem Laboratories Ltd - 539523 - Results- Financial Results For Quarter Ended June 30, 2021
In continuation of our letter dated 26th July, 2021 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we are enclosing the Standalone and Consolidated Unaudited Financial Results for the quarter ended 30th June, 2021, duly approved by the Board of Directors of the Company, at its meeting held today, i.e. 06th August, 2021. The meeting of the Board of Directors of the Company commenced at 11.00 A.M and concluded at 1.30 P.M. A copy of the Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the Listing Regulations, is also enclosed herewith. Kindly take the same on record.06-08-2021
Alkem Laboratories Ltd - 539523 - Board Meeting Outcome for Outcome Of The Board Meeting Dated 6Th Aug, 2021
The Board of Directors at its meeting held today i.e. 06th August, 2021, has approved the Standalone and Consolidated Unaudited Financial Results for the quarter ended 30th June, 2021. Accordingly, we are enclosing herewith Standalone and Consolidated Unaudited Financial Results for the quarter ended 30th June, 2021 and the Limited Review Report of the Statutory Auditors of the Company. The meeting of the Board of Directors of the Company commenced at 11 am and ended at 1. 30 pm.06-08-2021
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
This is to intimate you that Alkem Laboratories Limited (the 'Company') has launched Ibuprofen and Famotidine Tablets in the United States, following an approval from the United States Food and Drug Administration (US FDA). A press release in this regard is enclosed herewith. Kindly take the same on record.04-08-2021
Alkem Laboratories says USFDA inspection at Taloja facility ends with 'zero' observations
The US Food and Drug Administration (USFDA) had conducted a remote and virtual bio-analytical inspection of the company's Bioequivalence Center located at Taloja, Maharashtra from July 26-28, 2021, Alkem Laboratories said in a regulatory filing.29-07-2021
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
This is to inform you that US FDA had conducted a remote and virtual Bio-Analytical inspection of the Company's Bioequivalence Center located at Taloja, Maharashtra from 26th July, 2021 to 28th July, 2021. At the end of the inspection, no Form 483 was issued. Kindly take note of the same.29-07-2021
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to our earlier intimation dated 27th July, 2021 informing that a conference call shall be held on Friday, 06th August, 2021 at 04.30 pm to discuss the Q1FY22 financial results, please find enclosed herewith the revised details for the attending the said conference call. Kindly take note of the same.28-07-2021
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we write to inform you that a conference call to discuss the Q1FY22 financial results will be held on Friday, 06th August, 2021 at 04.30 pm. Please find attached herewith the conference call details. Kindly take note of the same.27-07-2021